INT24232

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.65
First Reported 1988
Last Reported 2011
Negated 0
Speculated 0
Reported most in Body
Documents 24
Total Number 24
Disease Relevance 8.06
Pain Relevance 7.99

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

mitochondrion (Mtx1)
Anatomy Link Frequency
neurons 2
urine 2
external 1
Mtx1 (Mus musculus)
Pain Link Frequency Relevance Heat
methotrexate 868 100.00 Very High Very High Very High
gABA 20 100.00 Very High Very High Very High
Arthritis 401 99.96 Very High Very High Very High
tetrodotoxin 4 99.34 Very High Very High Very High
Etanercept 256 98.36 Very High Very High Very High
Infliximab 94 88.88 High High
rheumatoid arthritis 137 87.76 High High
Glutamate 6 86.36 High High
cINOD 39 84.36 Quite High
Bioavailability 5 81.16 Quite High
Disease Link Frequency Relevance Heat
Juvenile Chronic Polyarthritis 320 99.96 Very High Very High Very High
Toxicity 82 99.80 Very High Very High Very High
Rheumatoid Arthritis 211 98.82 Very High Very High Very High
Disorder Of Lipid Metabolism 20 94.56 High High
Disease 155 86.72 High High
Congenital Anomalies 15 86.20 High High
Interstitial Lung Diseases 3 84.96 Quite High
Pulmonary Disease 5 79.92 Quite High
Targeted Disruption 6 79.12 Quite High
Systemic Lupus Erythematosus 12 78.80 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
CONCLUSIONS: For patients with active RA and intolerance or unsatisfactory response to MTX, substituting ETN for MTX and adding ETN to MTX are both effective ways of reducing disability, pain, disease activity, morning stiffness, and improving general health.


Localization (adding) of MTX
1) Confidence 0.65 Published 2008 Journal Ann. Rheum. Dis. Section Body Doc Link 17666447 Disease Relevance 0.10 Pain Relevance 0
CONCLUSIONS: For patients with active RA and intolerance or unsatisfactory response to MTX, substituting ETN for MTX and adding ETN to MTX are both effective ways of reducing disability, pain, disease activity, morning stiffness, and improving general health.


Localization (substituting) of MTX
2) Confidence 0.65 Published 2008 Journal Ann. Rheum. Dis. Section Body Doc Link 17666447 Disease Relevance 0.10 Pain Relevance 0
A previous study on adults with RA taking MTX showed that knowledge of the toxicity and safe use of MTX were significantly improved by a patient education program [3].
Localization (use) of MTX associated with toxicity, rheumatoid arthritis and methotrexate
3) Confidence 0.63 Published 2010 Journal Pediatr Rheumatol Online J Section Body Doc Link PMC2949753 Disease Relevance 1.09 Pain Relevance 0.36
Use of MTX for JIA patients in Japan
Localization (Use) of MTX associated with methotrexate and arthritis
4) Confidence 0.63 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2638602 Disease Relevance 1.09 Pain Relevance 1.05
The mean serum albumin binding rate of MTX was 42–57%.
Localization (rate) of MTX associated with methotrexate
5) Confidence 0.59 Published 2008 Journal Mod Rheumatol Section Body Doc Link PMC2638602 Disease Relevance 0.37 Pain Relevance 0.44
CONCLUSIONS: For patients with active RA and intolerance or unsatisfactory response to MTX, substituting ETN for MTX and adding ETN to MTX are both effective ways of reducing disability, pain, disease activity, morning stiffness, and improving general health.


Localization (response) of MTX
6) Confidence 0.57 Published 2008 Journal Ann. Rheum. Dis. Section Body Doc Link 17666447 Disease Relevance 0.10 Pain Relevance 0
were more likely to be receiving oral MTX (P < .0001).
Localization (receiving) of MTX associated with methotrexate
7) Confidence 0.51 Published 2010 Journal Human Genomics and Proteomics : HGP Section Body Doc Link PMC2958653 Disease Relevance 0.18 Pain Relevance 0.35
The initial target of MTX to be identified was dihydrofolate reductase (DHFR), which forms tetrahydrofolate, a precursor required for one carbon donation for synthesis of thymidylate, purines, methionine and serine, remethylation of homocysteine to form methionine, and provision of methyl donors for multiple methyltransferase enzymes [29].
Localization (target) of MTX associated with methotrexate
8) Confidence 0.51 Published 2010 Journal Human Genomics and Proteomics : HGP Section Body Doc Link PMC2958653 Disease Relevance 0.31 Pain Relevance 0.41
In ABCC2-deficient rats, MTX biliary excretion was significantly reduced [69].
Localization (excretion) of MTX associated with methotrexate
9) Confidence 0.48 Published 2010 Journal Human Genomics and Proteomics : HGP Section Body Doc Link PMC2958653 Disease Relevance 0.42 Pain Relevance 0.36
METHODS: Urinary excretion of MTX and its catabolite, 7-OH-MTX, was measured in 2 24-hour urine specimens collected after MTX therapy.
Localization (excretion) of MTX in urine
10) Confidence 0.43 Published 2009 Journal Arthritis Rheum. Section Body Doc Link 19644884 Disease Relevance 0.10 Pain Relevance 0
Patients with marked improvement in swelling and pain/tenderness indices had a lower mean 7-OH-MTX excretion level (P<0.05).
Localization (excretion) of MTX
11) Confidence 0.40 Published 2009 Journal Arthritis Rheum. Section Body Doc Link 19644884 Disease Relevance 0.06 Pain Relevance 0
Decreased 7-OH-MTX formation suggests folic acid inhibition of AO and a better clinical response, while increased 7-OH-MTX formation may interfere with MTX polyglutamylation and binding to enzymes and, therefore, may increase MTX excretion and decrease MTX retention and efficacy in vivo.


Localization (excretion) of MTX
12) Confidence 0.40 Published 2009 Journal Arthritis Rheum. Section Body Doc Link 19644884 Disease Relevance 0 Pain Relevance 0
METHODS: Urinary excretion of MTX and its catabolite, 7-OH-MTX, was measured in 2 24-hour urine specimens collected after MTX therapy.
Localization (excretion) of MTX in urine
13) Confidence 0.40 Published 2009 Journal Arthritis Rheum. Section Body Doc Link 19644884 Disease Relevance 0.10 Pain Relevance 0
Patients receiving MTX had fewer dropouts due to AEs when compared with patients receiving biologic therapy as monotherapy (p < 0.001).
Localization (receiving) of MTX associated with methotrexate
14) Confidence 0.39 Published 2006 Journal Arthritis Res Ther Section Body Doc Link PMC1794519 Disease Relevance 0 Pain Relevance 0.92
Relatively high 7-OH-MTX excretion was correlated with relatively high MTX excretion and with relatively low MTX retention in vivo (P<0.05) (n=35).
Localization (excretion) of MTX
15) Confidence 0.37 Published 2009 Journal Arthritis Rheum. Section Body Doc Link 19644884 Disease Relevance 0.05 Pain Relevance 0
drugs plus methotrexate (MTX) with MTX alone in patients with insufficient prior responses to MTX showed NNT values of 3 for ACR20, 4 for ACR50 and 8 for ACR70.
Localization (responses) of MTX associated with methotrexate
16) Confidence 0.22 Published 2008 Journal BMC Musculoskelet Disord Section Abstract Doc Link PMC2377247 Disease Relevance 0.43 Pain Relevance 0.59
The ADORE (ADd etanercept Or Replace MTX) trial was a 6-month open-label trial in patients with inadequate response to MTX (?
Localization (response) of MTX associated with methotrexate and etanercept
17) Confidence 0.12 Published 2008 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721350 Disease Relevance 0.16 Pain Relevance 0.86
MTX also induced a massive accumulation of 45Ca2+ in the neurons which, in contrast to the MTX-evoked GABA release, was totally blocked in the presence of 1 mM Co2+.
Localization (release) of MTX in neurons associated with gaba
18) Confidence 0.11 Published 1988 Journal J. Neurochem. Section Abstract Doc Link 2450172 Disease Relevance 0 Pain Relevance 0.34
Whereas 500 nM tetrodotoxin was without significant effect, MTX-evoked GABA release was dependent on the presence of external Na+ and sensitive to nipecotic acid, a GABA uptake inhibitor.
Localization (release) of MTX in external associated with tetrodotoxin and gaba
19) Confidence 0.11 Published 1988 Journal J. Neurochem. Section Abstract Doc Link 2450172 Disease Relevance 0 Pain Relevance 0.36
The effects of maitotoxin (MTX) on endogenous amino acid release were tested on highly purified striatal neurons differentiated in primary culture.
Localization (release) of MTX in neurons
20) Confidence 0.11 Published 1988 Journal J. Neurochem. Section Abstract Doc Link 2450172 Disease Relevance 0 Pain Relevance 0.11

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox